Biodel, Aegis sign licensing agreement for ProTek, Intravail technologies
News | 11 June 2012
Biodel and Aegis Therapeutics have signed a licensing agreement for ProTek and Intravail technologies for the development and commercialization of glucagon pharmaceutical formulations. According to the agreement, a variety of glucagon presentations ...
Click on the link to read the full article at Pharmaceutical Business Review
(This link will open in a new window)
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
